Indian grooming startup Bombay Shaving Company gets ₹45 crore investment from Dettol maker Reckitt Benckiser
Bombay Shaving Co.
Reckitt Benckiser(RB), the British consumer goods giant, has invested ₹45 crore in Bombay Shaving Company’s parent firm Visage Lines Personal Care.
- Earlier, the startup had raised funds from Colgate Palmolive among others.
- Having started off as a men’s grooming company, the startup had last year also ventured into women’s grooming products.
Earlier, the startup had raised funds from Colgate Palmolive, Sixth Sense Ventures and others.
The current investment round also saw participation from multiple High Net-worth individuals including Rajesh Sud from Bharti Enterprises, Anjali Bansal founder of Avaana Capital, and Kuldeep Jain, Managing Director of CleanMax Energy.
Having started off as a men’s grooming company, the startup had last year also ventured into women’s grooming products.
The five-year old startup is competing with the likes of Marico-acquired Beardo in the grooming industry. Bombay Shaving Company currently has over 2 million users, and with the fund infusion from RB hopes to achieve global scale.
“RB is a diamond addition to our journey. They have an excellent record in building health and wellness brands over their 200-years heritage. Working in partnership, our young team is ambitious for what we can achieve together and scale our operations with an omnichannel presence.” said Shantanu Deshpande, founder CEO of Visage Lines.
AdvertisementThe startup had also appointed Bollywood star Kartik Aaryan as its brand ambassador in 2020.
OnePlus co-founder Carl Pei launches a new consumer tech company and it's literally called Nothing
- Stocks to track on March 4 — HDFC, Airtel, Infosys, Adani Ports and others
- Deficit budget tabled in Arunachal Assembly with focus on
- DPR for piped water connection project announced in Rajasthan Budget to be ready by Aug 30: BD Kalla
- Budget session of Karnataka legislature to begin on Thursday
- Bharat Biotech’s Covaxin shows 81% efficacy after second dose in phase 3 trials